Nutex Health (NASDAQ:NUTX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Nutex Health (NASDAQ:NUTX) to a hold rating in a research note released on Monday morning,Zacks.com reports.

A number of other brokerages have also recently commented on NUTX. Weiss Ratings upgraded shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, May 4th. Lake Street Capital began coverage on shares of Nutex Health in a report on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 price objective for the company. Wall Street Zen raised shares of Nutex Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, B. Riley Financial started coverage on shares of Nutex Health in a report on Friday, June 26th. They set a “buy” rating and a $290.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $243.33.

Nutex Health Price Performance

NUTX opened at $170.89 on Monday. The company has a current ratio of 3.14, a quick ratio of 3.12 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $1.18 billion, a P/E ratio of 13.21 and a beta of 0.26. The stock has a 50-day moving average price of $131.86 and a 200-day moving average price of $129.94. Nutex Health has a 12-month low of $77.21 and a 12-month high of $193.07.

Nutex Health (NASDAQ:NUTX) last announced its quarterly earnings data on Thursday, April 30th. The company reported $6.52 earnings per share for the quarter, beating analysts’ consensus estimates of $3.99 by $2.53. The company had revenue of $216.49 million for the quarter, compared to analysts’ expectations of $227.80 million. Nutex Health had a return on equity of 23.50% and a net margin of 10.95%. Equities analysts predict that Nutex Health will post 22.72 earnings per share for the current fiscal year.

Institutional Trading of Nutex Health

Institutional investors have recently made changes to their positions in the stock. Islay Capital Management LLC bought a new position in shares of Nutex Health in the fourth quarter worth approximately $34,000. BNP Paribas Financial Markets raised its holdings in Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock valued at $40,000 after buying an additional 290 shares during the last quarter. Royal Bank of Canada raised its holdings in Nutex Health by 752.4% during the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after buying an additional 316 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Nutex Health by 280.3% during the 4th quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock valued at $133,000 after buying an additional 597 shares during the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in Nutex Health during the 1st quarter valued at $83,000. Hedge funds and other institutional investors own 5.32% of the company’s stock.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight?loss services and behavioral health support. By combining in?person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost?effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail?anchored centers, offering treatment for non?life?threatening injuries and illnesses, preventive screenings and basic primary care.